The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice titled “Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries” (BARDA-CBRN-07282026) to identify commercially available or near commercial technologies that address large-area skin loss from burns and traumatic injuries in a mass casualty setting. This notice is for planning purposes only and is intended to gather market data on pricing, inventory, capabilities, and product readiness across the current advanced wound care landscape.
For companies developing advanced wound care, regenerative medicine, or trauma-focused medical countermeasures, this is an early signal that BARDA is actively evaluating solutions that can temporize wound healing, accelerate closure, control infection, and support functional dermal regeneration in high-consequence response scenarios, including CBRN incidents.
Who Should Consider Submitting
BARDA is seeking input from both small businesses and other-than-small businesses that can develop, manufacture, and store advanced dermal regeneration substitutes. The notice is especially relevant to companies with products intended for:
- Full-thickness burns
- Complex traumatic wounds
- Blast injuries
- Other cases involving substantial skin and soft tissue loss
BARDA is most interested in technologies that are already commercialized or approaching commercial readiness. Strong candidates will be able to demonstrate:
- Clinical evidence supporting safety and effectiveness
- Scalable U.S. manufacturing capabilities
- Practical storage conditions (e.g., suitable for stockpiling and deployment)
- Operational fit for emergency or austere care settings
Core Capability Areas
BARDA notes that current standards of care for severe burns and complex traumatic injuries are constrained by supply chain complexity, donor site limitations, infection risk, delayed healing, and inconsistent functional and cosmetic outcomes. In response, the agency is exploring advanced dermal regeneration substitutes that can improve outcomes in both routine care and surge scenarios.
The notice highlights several core capability areas for candidate products, including:
- Dermal regeneration: ability to support vascularized neodermis, host tissue integration, and epithelialization.
- Infection control and barrier function: protection against microbes and reduced infection rates.
- Use‑case flexibility: ready‑to‑use or minimal preparation, ambient or practical stability, and suitability for long‑term stockpiling.
- Scalable U.S. manufacturing: reproducible, donor‑tissue independent processes with rapid scale‑up potential.
- Ease of use: deployment in austere and resource‑constrained settings without highly specialized surgical support.
- Clinical and regulatory maturity: supporting data, clear or emerging regulatory status, and a viable reimbursement path.
BARDA is open to fully synthetic, biosynthetic, and acellular or cellular dermal substitutes that can meet these functional and operational requirements.
What Respondents Need to Submit
Responses must include separate technical and business sections, together not exceeding 10 single‑sided pages, including attachments and charts. The technical section should cover regenerative capability, clinical data, regulatory status, instructions for use, manufacturing, and supply‑chain and production details. The business section should outline company background, U.S. operational capabilities, distribution rights, current pricing, future market projections where possible, and plans to grow in the U.S. burn and trauma market.
Responses are due by 4:00 PM ET on August 28, 2026, and must be submitted electronically to [email protected].
Any later solicitations will be posted on SAM.gov.
Why This Matters
This notice underscores ongoing federal efforts to strengthen medical countermeasure readiness for burn and trauma scenarios tied to CBRN incidents and other mass casualty events. It also signals potential interest in vendor‑managed inventory for advanced dermal regeneration substitutes, which could create future pathways for stockpiling and preparedness investment.
For regenerative medicine and advanced wound care companies, responding to this Sources Sought is a chance to put existing products and pipelines on BARDA’s radar before formal requirements are locked in.
EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, ensuring you win the award and deliver the program.
For additional information on where your capabilities could plug into this investment, schedule a conversation with our team.
